Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Hiring Stern

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Aug 18, 2020 4:30pm

178 Views

Post# 31424943

RE:RE:RE:RE:RE:RE:RE:Hiring Stern

Disagree.

1-You are conflating the significance of the "tylenol significance". Again on par with other NSAIDs, single digit percentage of elevated AST (which can happen with any activity, such as from a long walk or hike) that was discussed ad nauseum on the dock side chat in bio pub, and can't be directly attributed to 346, espeically when compared to the GI safety data.

2- While neither of us can read minds, but I do not think any member of the board at ATE believes the company is worth $0.40/share. That deal was made, for various reasons (All mentioned in the prospectus), after over $150mil worth of capital evaportated when retail investors panicked.

3- the insider trades were already approved prior to results back in november 2019.

4 This may be your dumbest comment yet "Stern will--If they are the top pros they were hired to be, and are being paid to be, around five months into their six month contract--sit Dan down and explain to him the facts of life."

Blazesb wrote: Antibe trades at .40 today. That's what Dan Legault thinks its worth. Baked into that price is the entirety of phase 2 data including acetaminophen 'significance'.

I posted about Stern to clarify what it could do for Antibe which includes what has to this time been missing: a proper response to phase 2 with reference to acetaminophen 'significance'. I've included that post below.

Hiring Stern

...was the best thing management has done to advance Antibe.

Unlike many here i remain a realist about Antibe's immediate future. I believe Antibe will receive partnership offers and will turn them down because the offers will not price in the potential and upside in 346.

Antibe will be 'lowballed'. The reason why is because of the acetaminophin 'significance' that crushed Antibe's share price when otherwise brilliant phase 2 data was released.

Potential partners will not pay a premium for potential until that 'significance' is erased by further data. This means phase 3 results that address the acetaminophin 'significance'.

Presently the company is pretending all is well.

Stern will--If they are the top pros they were hired to be, and are being paid to be, around five months into their six month contract--sit Dan down and explain to him the facts of life.

Antibe must come clean, preferably in the highest profile industry journal possible, about the acetaminophen significance. The article should explain that the initial phase 3 tests of 346 will have more patients, more doses over longer periods and all will include post test acetaminophin results that will be clinically 'insignificant'.

That's what top public relations people do for their clients.

Then, Antibe can resume it's inevitable rise premised on the superior science behind 346. Presently, that science is under a cloud creating the present situation which must be addressed.